ANTIGENICS INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 22nd, 2008 • Armen Garo H • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is made and entered into as of January 9, 2008, by and among Antigenics Inc., a Delaware corporation (the “Company”) and the investors identified on Schedule I attached hereto (each, a “Purchaser”, and collectively, the “Purchasers”).
VOTING AGREEMENTVoting Agreement • February 16th, 2016 • Armen Garo H • Services-business services, nec • New York
This VOTING AGREEMENT (this “Agreement”) is entered into as of February 12, 2016 (the “Effective Date”) by and among Atrinsic, Inc., a Delaware corporation (the “Company”), the parties listed as stockholders of Protagenic Therapeutics, Inc. (the “Protagenic Therapeutics Stockholders”) on the signature pages hereto, and Strategic Bio Partners, LLC (“Strategic”), each such person a “Stockholder” and collectively, the “Stockholders”.
JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2024 • Armen Garo H • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $.00001 per share, of MiNK Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as Exhibit 99.1.
